The results indicate that baricitinib offers a potential therapeutic option with a favourable benefit-risk profile for paediatric patients with moderate-to-severe AD who are candidates for systemic therapies.
No takes yet. Share an insight, caveat, or question.
Torrelo et al. (2023) studied this question.